The inmunogen Mambisa, in all the groups studied, induced an anti-RBD response in more than four times with respect to the initial level and its inhibitory capacity against SARS-COV 2 was increased by more than 20% at systemic level and in nasal mucosa.

The Cuban vaccine candidate Mambisa, is the first nasal vaccine candidate to start human clinical trials in the world.

The Center for Genetic Engineering and Biotechnology-developer of the drug-reported on Twitter that the inmunogen is advancing in its application to convalescents and as a booster dose, demonstrating safety and immunogenicity.

Theses parameters were demonstrated during the development of a Phase I/II clinical trial, adaptative, randomized, parallel group, applied in 120 convalescent adults, BiocubaFarma pointed out in the same social network.

In Phase I, three oral administration devices were compared, two of them in the form of atomization and another one in the form of drops.

With all three devices, the vaccine candidate proved to be safe. The adverse events that were described were mostly mild and no serious events occurred, the company said.

In all the groups studied, Mambisa induced anti-RBD response more than four times higher than the initial level, increasing its inhibitory capacity against SARS-COV 2 virus by more than20% at systemic level and in the nasal mucosa.

Eduardo Martínez Díaz , president of BiocubaFarma has assured that the inmunogen, by acting in one of the entry doors of the pathogen to the organism, Mambisa could achieve what have been so far impossible : cut the transmission of Coronavirus.

Source: Gramma